Understanding the Drug-Eluting Stent Trials

American Journal of Cardiology

Volumn 100, Issue 5 SUPPL., 2007, Pages

  Coolong, Alanna ^a   Kuntz, Richard E ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 578; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EVEROLIMUS; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PACLITAXEL; POLYMER; RAPAMYCIN;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; HUMAN; IN-STENT RESTENOSIS; MATERIAL COATING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTENOSIS; RISK FACTOR; RISK REDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG DELIVERY SYSTEMS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PACLITAXEL; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SIROLIMUS; STENTS; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 34547932038     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.06.004     Document Type: Article

References (43)

1. American Heart Association. Heart Disease and Stroke Statistics- 2004 Update (2003), American Heart Association, Dallas, TX
2. Greenberg D., Bakhai A., and Cohen D.J. Can we afford to eliminate restenosis?. Can we afford not to?. J Am Coll Cardiol 43 (2004) 513-518
3. Weintraub W.S., Mauldin P.D., Becker E., Kosinski A.S., and King III S.B. A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease: results from the Emory Angioplasty Versus Surgery Trial (EAST). Circulation 92 (1995) 2831-2840
4. Hlatky M.A., Rogers W.J., Johnstone I., Boothroyd D., Brooks M.M., Pitt B., Reeder G., Ryan T., Smith H., Whitlow P., Wiens R., Mark D.B., and Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery. N Engl J Med 336 (1997) 92-99
5. Weintraub W. The pathophysiology and burden of restenosis. Am J Cardiol 100 suppl (2007) 3K-9K
6. Degertekin M., Regar E., Tanabe K., Smits P.C., van der Giessen W.J., Carlier S.G., Feyter P., Vos J., Foley D.P., Ligthart J.M., Popma J.J., and Serruys P.W. Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol 41 (2003) 184-189
7. Morice M.-C., Serruys P.W., Sousa J.E., Fajadet J., Ban Hayashi E., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., Falotico R., and RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions: a randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346 (2002) 1773-1780
8. Serruys P.W., Degertekin M., Tanabe K., Abizaid A., Sousa J.E., Colombo A., Guagliumi G., Wijns W., Lindeboom W.K., Ligthart F., de Feyter P.J., Morice M.-C., and RAVEL Study Group. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 106 (2002) 798-803
9. Fajadet J., Morice M.-C., Bode C., Barraged P., Serruys P.W., Wijns W., Constantini C.R., Guermonprez J.L., Eltchaninoff H., Blanchard D., et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111 (2005) 1040-1044
10. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
11. Leon MB. A cross-section of US perspectives on drug eluting stents-the great "non-debate" a: why Cypher is better [slide kit lecture]. Presented at TCT at EuroPCR 2004 Conference; May 27, 2004; Paris, France. Slide 45. Available at: http://www.europcronline.com/fo/lecture/affiche_diapo.php?id=1437. Accessed May 10, 2007.
12. Holmes D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., and Brown C. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
13. Weisz G., Leon M.B., Holmes D.R., Keriakes D.J., Clark M.R., Cohen B.M., Ellis S.G., Coleman P., Hill C., Shi C., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol 47 (2006) 1350-1355
14. Schofer J., Schluter M., Gershlick A.H., Wijns W., Garcia E., Schampaert E., Breithardt G., and E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 362 (2003) 1093-1099
15. Schampaert E., Cohen E.A., Schlüter M., Reeves F., Traboulsi M., Title L.M., Kuntz R.E., Popma J.J., and C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 43 (2004) 1110-1115
16. Ardissino D., Cavallini C., Bramucci E., Indolfi C., Marzocchi A., Manari A., Angeloni G., Carosio G., Bonizzoni E., Colusso S., Repetto M., Merlini P.A., and SES-SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 292 (2004) 2727-2734
17. Schampaert E., Moses J.W., Schofer J., Schlüter M., Gershlick A.H., Cohen E.A., Palisaitis D.A., Breithardt G., Donohoe D.J., Wang H., et al., SIRIUS, E- and C-SIRIUS Investigators. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol 98 (2006) 36-41
18. Schluter M., Schofer J., Gershlick A.H., Schampaert E., Wijns W., Breithardt G., and E- and C-SIRIUS Investigators. Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: a post hoc subanalysis of the pooled E- and C-SIRIUS trials. J Am Coll Cardiol 45 (2005) 10-13
19. Sabaté M., Jiménez-Quevedo P., Angiolillo D.J., Gómez-Hospital J.A., Alfonso F., Hernández-Antolín R., Goicolea J., Bañuelos C., Escaned J., Moreno R., et al., DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the Diabetes and Sirolimus-Eluting Stent (DIABETES) trial. Circulation 112 (2005) 2175-2183
20. Kelbaek H., Thuesen L., Helqvist S., Kløvgaard L., Jorgensen E., Aljabbari S., Saunamaki K., Krusell L.R., Jensen G.V., Botker H.E., et al., SCANDSTENT Investigators. The stenting coronary arteries in non-stress/benestent disease (SCANDSTENT) trial. J Am Coll Cardiol 47 (2006) 449-455
21. Rowinsky E.K., and Donehower R.C. Paclitaxel (taxol). N Engl J Med 332 (1995) 1004-1014
22. Grube E., Silber S., Hauptmann K.E., Mueller R., Buellesfeld L., Gerckens U., and Russell M.E. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107 (2003) 38-42
23. Colombo A., Drzewiecki J., Banning A., Grube E., Hauptmann K., Silber S., Dudek D., Fort S., Schiele F., Zmudka K., Guagliumi G., Russell M.E., and TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 108 (2003) 788-794
24. Stone G.W., Ellis S.G., Cox D.A., Hermiller J., O'Shaughnessy C., Mann J.T., Turco M., Caputo R., Bergin P., Greenberg J., Popma J.J., Russell M.E., and TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109 (2004) 1942-1947
25. Stone G.W., Ellis S.G., Cannon L., Tift Mann J., Greenberg J.D., Spriggs D., O'Shaughnessy C.D., DeMaio S., Hall P., Popma J.J., Koglin J., Russell M.E., and TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 294 (2005) 1215-1223
26. Dawkins K.D., Grube E., Guagliumi G., Banning A.P., Zmudka K., Colombo A., Thuesen L., Hauptman K., Marco J., Wijns W., et al., TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 112 (2005) 3306-3313
27. Lansky A.J., Costa R.A., Mintz G.S., Tsuchiya Y., Midei M., Cox D.A., O'Shaughnessy C., Applegate R.A., Cannon L.A., Mooney M., et al., DELIVER Clinical Trial Investigators. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 109 (2004) 1948-1954
28. Gershlick A., De Scheerder I., Chevalier B., Stephens-Lloyd A., Camenzind E., Vrints C., Reifart N., Missault L., Goy J.J., Brinker J.A., et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109 (2004) 487-493
29. Goy J.-J., Stauffer J.-C., Siegenthaler M., Benoît A., and Seydoux C. A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. J Am Coll Cardiol 45 (2005) 308-311
30. Morice M.-C., Colombo A., Meier B., Serruys P., Tamburino C., Guagliumi G., Sousa E., Stoll H.-P., and REALITY Trial Investigators. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY Trial. A randomized controlled trial. JAMA 295 (2006) 895-904
31. Windecker S., Remondino A., Eberli F.R., Jüni P., Räber L., Wenaweser P., Togni M., Billinger M., Tüller D., Seiler C., et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 353 (2005) 653-662
32. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., Schomig A., and Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
33. Dibra A., Kastrati A., Mehilli J., Pache J., Schühlen H., von Beckerath N., Ulm K., Wessly R., Dirschinger J., Schömig A., and ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 253 (2005) 663-670
34. Kastrati A., Dibra A., Eberle S., Mehilli J., de Lezo J.S., Goy J.J., Ulm K., and Schomig A. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA 294 (2005) 819-825
35. Meredith I.T., Ormiston J., Whitbourn R., Kay P., Muller D., Bonan R., Popma J.J., Cutlip D.E., Fitzgeald P., Prpic R., and Kuntz R.E. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 1 (2005) 157-164
36. Fajadet J., Wijns W., Laarman G.-J., Kuck K.-H., Ormiston J., Münzel T., Popma J.J., Fitzgerald P.J., Bonan R., Kuntz R.E., and ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the Endeavor II trial. Circulation 114 (2006) 798-806
37. US National Institutes of Health. The ENDEAVOR III Clinical Trial. [ClinicalTrials.gov/National Library of Medicine Website.]. Available at: http://www.clinicaltrials.gov/ct/show/NCT00217256. Accessed November 21, 2006.
38. US National Institutes of Health. The ENDEAVOR IV Clinical Trial. [ClinicalTrials.gov/National Library of Medicine Website.]. Available at: http://www.clinicaltrials.gov/show/NCT00217269. Accessed November 21, 2006.
39. Serruys P.W., Ong A.T.L., Piek J.J., Neumann F.-J., van der Giessen W.J., Wiemer M., Zeihner A., Grube E., Hasse J., Thuesen L., Hamm C., and Otto-Terlouw P.C. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1 (2005) 58-65
40. Tsuchiya Y., Lansky A.J., Costa R.A., Mehran R., Pietras C., Shimada Y., Sonoda S., Cristea E., Negoita M., Dangas G.D., et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 98 (2006) 464-469
41. US National Institutes of Health. Spirit II Clinical Trial. Available at: http://www.clinicaltrials.gov/show/NCT00180310. Accessed November 21, 2006.
42. US National Institutes of Health. Spirit III Clinical Trial. [ClinicalTrials.gov/National Library of Medicine Website.]. Available at: http://www.clinicaltrials.gov/show/NCT00180479. Accessed November 21, 2006.
43. US National Institutes of Health. Spirit IV Clinical Trial. [ClinicalTrials.gov/National Library of Medicine Website.]. Available at: http://www.clinicaltrials.gov/show/NCT00307047. Accessed November 21, 2006.